Knowledge, Perceptions and Information about Hormone Therapy (HT) among Menopausal Women: A Systematic Review and Meta-Synthesis

MinFang Tao1, YinCheng Teng1, HongFang Shao1, Ping Wu2, Edward J. Mills2,3

1 Department of Gynecology, Shanghai Jiao Tong University, Affiliated Sixth People’s Hospital, Shanghai, China, 2 Faculty of Health Sciences, University of Ottawa, Ottawa, Canada, 3 Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Canada

Abstract

**Background:** The use of hormone therapy (HT) by menopausal women has declined since the Women’s Health Initiative randomized trial (WHI) in 2002 demonstrated important harms associated with long-term use. However, how this information has influenced women’s knowledge and attitudes is uncertain. We aimed to evaluate the attitudes and perceptions towards HT use, as well as specific concerns and information sources on HT since the WHI trial.

**Method/Results:** We did a systematic review to assess the attitudes and knowledge towards HT in women, and estimate the magnitude of the issue by pooling across the studies. Using meta-synthesis methods, we reviewed qualitative studies and surveys and performed content analysis on the study reports. We pooled quantitative studies using a random-effects meta-analysis. We analyzed 11 qualitative studies (n = 566) and 27 quantitative studies (n = 39251). Positive views on HT included climacteric symptom control, prevention of osteoporosis and a perceived improvement in quality of life. Negative factors reported included concerns about potential harmful effects, particularly cancer risks. Sources of information included health providers, media, and social contact. By applying a meta-synthesis approach we demonstrate that these findings are broadly applicable across large groups of patients.

**Conclusions:** Although there are clear hazards associated with long-term HT use, many women view HT favorably for climacteric symptom relief. Media, as a source of information, is often valued as equivalent to health providers.

Introduction

Hormone therapy has been one of the most broadly prescribed medications in recent memory. Although initially recommended for climacteric symptom control, there was a widespread misunderstanding in the medical community that HT offered many favorable additional effects including cardiovascular and neurological protection [1,2,3]. Because menopause naturally occurs when the ovaries begin decreasing production of estrogen and progesterone, and induced menopause occurs when the ovaries are surgically removed by bilateral oophorectomy or damaged by radiation or drugs, it usually takes 10 years for women to experience symptomatic changes. This is typically in a woman’s late forties or early fifties, a time when lifestyle and other progressive diseases may become apparent. During this stage, many women experience physical and/or emotional symptoms [4,5]. For some, symptoms related to menopause importantly impact their daily personal, professional, and social lives, resulting in a desire to reduce any adverse symptoms [6,7].

With widespread support of HT for broad health benefits, single small trials or observational studies did not provide sufficient evidence to change the larger medical opinion. A large observational study, the Heart and Estrogen/progestin Replacement Study (HERS) [8] concluded that during 4.1 years of follow-up, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of coronary heart disease (CHD) events in postmenopausal women with established coronary disease; on the contrary, it increased the rate of thromboembolic events and gallbladder disease. In 2002, the Women’s Health Initiative (WHI) randomized trial involving over 26,000 women [9] was stopped early due to increased risks of invasive breast cancer, pulmonary embolism, CHD and stroke when compared with placebo, confirming the findings of the HERS study [10]. A meta-analyses of observational studies published in 2002 indicated that HT was associated with long-term important harms, and a benefit only at osteoporosis prevention and climacteric relief [11]. The follow-up WHI study demonstrated HT was responsible for breast cancer and excess deaths directly attributed to breast cancer [12].

Despite evidence from these large studies, as many as 50% of physicians remain skeptical toward the evidence from WHI and HERS, citing concerns with study designs and patient populations...
Further, industry involvement in clinician and patient education has led to concern that benefits of HT are being unnecessarily promoted and harms are being reduced [14]. For this reason, it may be challenging for health care providers and menopausal women to make informed decisions on HT use. Although the use of HT has decreased [15,16], there is uncertainty among obstetrician-gynecologists that it may be a viable treatment option for climacteric symptoms relief such as hot flashes, vaginal atrophy, osteoporosis and loss of Libido [17]. While studies have examined the knowledge and perceptions of physician and healthcare providers about the evidence for HT [13,17,18], no systematic review about the overall attitude or perception of menopausal women towards HT exist. In order to summarize women’s attitudes and knowledge regarding HT use, we applied a meta-synthesis of published studies [19,20,21], a strategy that permits reviewers to identify common perceptions and beliefs and to determine the magnitude of these beliefs with some confidence.
Materials and Methods

Study approach

Our study approach is based on a two-step analysis of the studies. Firstly, we will identify the themes that are identified in qualitative studies. Secondly, we will determine the magnitude of these themes in broader populations by conducting a meta-analysis of surveys that report the themes. We have published on these methods extensively in the past [19,20,21,22,23,24].

Eligibility criteria

For stage 1, we included two types of studies, qualitative studies and quantitative studies that used open-ended questions, allowing an unlimited number of participant responses. For stage 2, we
included qualitative studies that report on the proportion of survey populations that affirm the issues raised in qualitative studies.

Eligible studies had to meet the following criteria: reported as an original research study and conducted in peri-menopausal women; contained information addressing attitude or knowledge towards HT; or information sources on HT. Studies that only compared the demographic characteristics between HT users and non-users; evaluated clinical outcomes; evaluated the proportion of HT use; or conducted within a specific population (eg. patients with breast cancer or cardiovascular diseases) were excluded.

**Search strategy**

Using a formal search strategy, MFT and YCT searched the following databases independently and in duplicate (from 07/2002 to 01/2011): MEDLINE, AMED, Alt Health Watch, CINAHL, Nursing and Allied Health Collection: Basic, and the Cochrane Database of Systematic Reviews. Our search strategy used permutations and combinations of the following terms: attitudes, perception, knowledge, behavior and belief, menopause, hormone treatment, HRT, qualitative, grounded theory, interview, questionnaire, cross-sectional and, survey. In addition, we supplemented this search by reviewing the bibliographies of key papers. We worked together to assess relevant studies for inclusion and only English language studies were included. MFT and YCT independently reviewed the abstracts and chose the full articles after discussion.

**Data abstraction and validity assessment**

MFT and HFS independently extracted data and appraised the validity. Disagreements were resolved by a third reviewer (PW). We extracted data on the methods of the studies using a modified checklist to assess internal validity [21] [25]. Quantitative studies were not scored as no accepted criteria exist for judging quality. A coding template to categorize key perceptions towards HT was developed iteratively during an initial review. This template consisted of the mutually exclusive headings listed as the positive factors that enable women to use; the negative factors that enable women to use; women’ individual characteristics when making the decision and information sources of HT.

We then read all available surveys to determine whether they asked questions broadly representative of the themes identified in the qualitative studies. Data were regarded eligible for inclusion in the meta-analysis if the study reported proportions of respondents.

**Statistical analyses**

We used the $\kappa$ statistic to measure chance-adjusted agreement between reviewers for study eligibility. When information on proportions of respondents was available from the quantitative studies, we calculated weighted proportions of studies using the Freeman-Tukey method [26]. We calculated an overall estimate of effect by pooling the proportions of each quantitative study by applying a random-effects model, with 95% Confidence Intervals (CI) and lower CI truncated at zero. We assessed heterogeneity of proportions visually as pooling proportions always results in large estimates of heterogeneity and statistical techniques do not yet exist to interpret the extent of real between-study heterogeneity for proportions [27]. We used Stats Direct for all statistical procedures.

**Results**

Our search identified 220 relevant abstracts. There was good ($\kappa = 0.64$) agreement between MFT and YCT on choosing the final 77 applicable full-text studies for potential inclusion. Of these studies, 40 were excluded for various reasons, leaving 37 studies [5,7,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62] included in our analyses (See figure 1).

We included eleven qualitative studies [40,53,54,55,56,57,58,59,60,61,62] and 27 quantitative studies [7,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,63], reporting 31 independent studies. One study [40] included both qualitative and quantitative study. Table 1 shows the characteristics of the populations in the qualitative studies and Table 2 shows the methodology of these studies. Among these, 4 studies [40,56,60,62] used focus groups (n = 248), five [53,54,57,58,59]
used semi-structured interviews (n = 151), one [61] used both focus
group and semi-structured interviews (n = 40) and one [55] used
mainly open-ended questioning (n = 127). The attitudes identified
towards HT are listed in Table 3.

The characteristics of all quantitative studies are listed in Table 4
and whether they used structured questionnaires or structured
interviews (n = 39,251) to determine the attitude and acknowl-
dgement of HT (see Table 5 for the details). Studies were

| Table 3. Attitude towards HT in qualitative studies. |
|-----------------------------------------------------|
| reference | Walter 2002 [61] | French 2006 [55] | Ballard 2002 [53] | Cifcili 2009 [54] | Shelton 2002 [60] | Loutfy 2006 [40] | Hepworth 2002 [56] | Hyde 2010 [57] | Kolip 2009 [58] | Weltom 2004 [62] | Nekhlyudov 2009 [59] |
| Positive factors that enable women to use | | | | | | | | | | |
| Effective for climacteric symptoms | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Benefit outweighs risk | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Osteoporosis prevention | ✓ | |
| Treatment of menopause related disease | ✓ | |
| Necessary supplement | ✓ | ✓ | |
| Improve quality of life | ✓ | ✓ | |
| MD recommendation | ✓ | ✓ | ✓ | ✓ | |
| Negative factors that enable women to use | | | | | | | | | | |
| Potential side effects | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| May cause cancer | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| May cause CHD | ✓ | |
| Uncertain evidence | ✓ | ✓ | ✓ | ✓ | |
| No benefit or bad solution of HT | ✓ | |
| Distrust HT | ✓ | |
| Against person’s natural healing process | ✓ | |
| Experiment with my body | ✓ | |
| No knowledge about HT | ✓ | |
| Reduce life quality | ✓ | |
| Not suggested by MD | |
| Women’s individual characteristics when making the decision | | | | | | | | | | |
| Preference for other treatment | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Unnecessary to use | ✓ | |
| Personal experience, knowledge against HT use | ✓ | ✓ | ✓ | |
| Dislike medication/HT isn’t natural | ✓ | |
| Concern of the cost | ✓ | |
| Feel isolation when making decision | ✓ | |
| Medical history contraindicate HT use | ✓ | |
| Fear/Mistrust of research | ✓ | |
| Information sources | | | | | | | | | | |
| Media | ✓ | ✓ | |
| Work and social contact | ✓ | ✓ | |
| Health professional | ✓ | ✓ | |
| Women’s expectation | | | | | | | | | | |
| Communication with MD in decision making | ✓ | ✓ | ✓ | |
| Belief that MD should make decisions | ✓ | ✓ | ✓ | ✓ | |
| Favor evidence-based information | ✓ | ✓ | ✓ | |
| Balancing individualized situation | ✓ | ✓ | ✓ | ✓ | |
| ✓ indicates that the items was reported in the original text. |

doi:10.1371/journal.pone.0024661.t003
completed in Asia [7,28,29,35,48,51,63], Europe [7,32,34,36,38,39,43,44,45,46,49], North America [33], Latin America [7], Oceania [47] and the Middle East [40].

To generalize the findings from qualitative studies, we pooled data for the factors reported in quantitative studies. From the pooled data we found that 47% (95%:34–60%) of participants perceived that HT was effective for climacteric symptoms, 26% (95%:15–40%) perceived that HT could be used in osteoporosis prevention and 33%(19%–48%) thought the benefits of HT outweigh the risks.

Thirty-one percent (95%CI: 18–46%) were aware of potential adverse events of HT, 37% (95%:21–54%) aware HT may cause cancer and 14% (95%: 3–31%) thought the risks of HT outweigh its benefit. Thirty-four percent (95%: CI: 21–48%) thought it was unnecessary to use HT as the menopause-related symptoms were tolerable; 35% (95%:24–47%) of respondents felt that the current evidence on HT was uncertain and 49%(95%: CI: 22–76%) mentioned that they had no knowledge about HT.

For information sources, forty-three percent (95%CI: 26–60%) obtained menopause- and HT related information from media including TV, internet, magazines, and newspapers, while 47% (95%CI: 25–70) obtained information from their health care provider and 40% (95%CI: 17–65) from their work or social contacts. No knowledge of HT was evaluated in 7 studies, and 5 of them was conducted in developing countries,. We found visible heterogeneity in all pooled analyses, which we explain by our a priori hypotheses that findings from developed countries differ from developing countries in terms of knowledge. Figure 2 shows the pooled proportions of attitudes that were generated from the outcomes listed in Table 5.

Discussion

In our current review, we summarized women’s attitude and perceptions towards HT reported in studies published after the WHI and found somewhat low levels of concern about serious adverse events. In addition, with the development of information

### Table 4. Characteristics of quantitative studies.

| reference   | Num | country     | age  | Education(>9 ys) (%) | Response rate (%) | Never use HT(%) |
|-------------|-----|-------------|------|----------------------|--------------------|-----------------|
| Lam PM 2003 21 | 978  | Hong Kong  | 40–60 | 47                   | na                 | 96              |
| Kaur S 2004 22 | 725  | India      | 40–60 | 13                   | na                 | 100             |
| Barber CA 2004 23 | 185  | USA        | 25–84 | 72                   | 98                 | 100             |
| Obermeyer CM 2004 24 | 293  | USA        | 45–55 | 98                   | 62                 | 71              |
| Ekstrom H 2005 25 | 1681 | Sweden     | 45–60 | 49                   | 76                 | 59              |
| Filho A 2005 26 | 755  | Brazil     | > = 35 | 100               | 66                 | 29              |
| Hovi S 2005 27 | 778  | Finland    | 45–64 | 61                   | 66                 | 90              |
| Chaopatpong P 2005 28 | 148  | Thailand   | > = 40 | 87                 | 91                 | 76              |
| Thunell L 2005 29 | 4095 | Sweden     | > = 46 | 43                 | 76                 | na              |
| Thunell L 2005 29 | 4504 | Sweden     | > = 46 | 77                 | 76                 | 27              |
| Bosworth HB 2005 30 | 533  | USA        | 45–54 | 76                   | 22                 | 50              |
| Genazzani AR 2006 31 | 4201 | Europe     | 45–60 | 79                   | na                 | 58              |
| Sveinsdottir H 2006 32 | 561  | Iceland    | 47–53 | 69                   | 56                 | 55              |
| Loutfy I 2006 33 | 450  | Egypt      | 50–59 | 21                   | na                 | 100             |
| Twiss JJ 2007 34 | 166  | USA        | 40–55 | 99                   | 54                 | na              |
| Rigby AJ 2007 35 | 781  | USA        | 40–60 | 89                   | 72                 | 66              |
| Uncu Y 2007 36 | 1007 | Turkey     | 39–89 | 13                   | na                 | 83              |
| Castelo-Branco C 2007 37 | 270  | Spain      | 40–65 | 35                   | na                 | 33              |
| Lindh L 2007 38 | 1180 | Sweden     | 53–54 | na                 | 67                 | 48              |
| Lindh L 2007 39 | 1239 | Sweden     | 53–54 | 68                   | 72                 | 56              |
| Heinemmann K 2008 3 | 4791 | Europe     | 40–70 | 19                   | 70                 | 62              |
| Heinemmann K 2008 3 | 1500 | USA        | 40–70 | 40                   | 70                 | 57              |
| Heinemmann K 2008 3 | 3006 | Latin America | 40–70 | 9                   | na                 | 80              |
| Heinemmann K 2008 3 | 1000 | Indonesia | 40–70 | 4                   | na                 | 98              |
| Deeks A 2008 40 | 692  | Australia  | 45–55 | na                 | 77                 | na              |
| Malik HS 2008 41 | 102  | Pakistan  | 40–75 | “No education” 60.8 | 93                 | 100             |
| Donatti S 2009 42 | 720  | Italy      | 45–64 | 44                   | 74                 | 84              |
| Huston SA 2009 43 | 689  | USA        | 45–64 | 99                   | 42                 | 56              |
| Jassim GA 2009 44 | 260  | Bahrain   | 30–64 | 86                   | na                 | 97              |
| Simon JA 2009 45 | 961  | USA        | > = 35 | 69                 | 69                 | 59              |
| Huang K 2010 63 | 1000 | Asia       | 45–60 | 100                | na                 | 45              |
Table 5. Attitude towards HT identified in quantitative study.

| reference                  | Deeks2008 | Twiss2007 | Heinemann2008 | Simon2009 | Jassim 2009 | Huston2009 | Lam2003 | kaur2004 | Thunell2005 | Malik2008 | Bosworth2005 | Chaopotong2005 | Lindh2007 | Huang 2010 |
|----------------------------|-----------|-----------|----------------|------------|-------------|------------|----------|---------|-------------|-----------|--------------|---------------|------------|------------|
| **Positive factors that enable women to use** |           |           |                |            |             |            |          |         |              |           |              |                |            |            |
| Effective for dimaeric symptoms | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| benefit overweighs risk       | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Osteoporosis prevention      | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Treatment of diagnosed menopause related disease | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| HT is a necessary supplement | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Improve life quality         | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| MD recommendation            | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| **Negative factors that enable women to use** |           |           |                |            |             |            |          |         |              |           |              |                |            |            |
| Potential side effects       | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| May cause cancer             | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| May cause CHD                | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| May cause cancer             | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| uncertain evidence            | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| No benefit or bad solution of HT | ✓       | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| No knowledge about HT        | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Not suggested by MD          | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Vaginal bleeding             | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| **Women’s individual characteristics when making the decision** |           |           |                |            |             |            |          |         |              |           |              |                |            |            |
| Preference for other treatment | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Unnecessary to use           | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Personal experience, knowledge against HT use | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Dislike medication/HT is not natural | ✓       | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Concerns of the cost         | ✓         | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Feels unsupported in decision making | ✓       | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Medical history contraindicate HT use | ✓       | ✓         | ✓              | ✓          | ✓           | ✓          | ✓        | ✓        | ✓            | ✓         |              |                |            |            |
| Information sources          |           |           |                |            |             |            |          |         |              |           |              |                |            |            |
technology, we also found media sources share a similar status as healthcare and have become a commonly used form of information. Women in developing countries had lower levels of knowledge about HT than those in more developed settings. These findings are concerning for several reasons. First, many obstetrician-gynecologists have reported they were unlikely to change their prescribing practice following the WHI [17]. And secondly, emerging evidence indicates sources of information on HT benefits and harms may be skewed according to the funding body supporting the messaging, potentially downplaying risks associated with HT [15].

There are both strengths and weaknesses to consider when interpreting our study. A novelty of our study is that we synthesized and conducted a meta-analysis based on issues raised in qualitative studies and then assessed the magnitude of these beliefs in larger populations by pooling the answers from the quantitative studies. We have used this approach several times previously on unrelated topics [19,20,21,22,23,24] and have published its methodological assumptions [20,22]. Limitations of our study lie most inherently in the reporting biases presented in the included qualitative studies. Unlike protocol driven studies, such as randomized trials, where the outcomes should be established prior to the conduct of the study, one cannot determine what issues will be conclusively raised in qualitative studies. Thus, it is possible that some issues raised by participants are not reported in the final manuscripts. For that reason, we believe our approach is specific but not necessarily sensitive, our approach to pooling utilized proportions, an infrequently used metric to apply meta-analysis to. Although several methods of weighting proportions exist, we used the Freeman-Tukey method as we have evaluated its performance previously in meta-analysis [23,64]. The choice of weighting proportions approach does not change the results of a meta-analysis importantly. We assessed heterogeneity visually and explained heterogeneity using a priori explanations of heterogeneity, specifically, geographic location of the study. Common methods of assessing heterogeneity do not perform well with proportions and appear to overestimate heterogeneity even when it is low [27].

Although in 2011, the use widespread use of HT seems misguided, HT has been broadly applied in clinical medicine for several decades. There is, however, consensus that HT is effective at climacteric symptoms reduction and osteoporosis prevention [65,66]. Although many women benefit from intermittent HT use, the concerns about longer-term adverse events frequently outweigh the short-term benefits. In 2005, the boards of the international, the Asian pacific, the European and the North American menopause society conducted post-hoc analyses of the WHI trial and noted that advanced age of the participants was importantly associated with adverse events. Concern about adverse events has also diminished the use of HT. HT use has declined by up to 62% since the WHI [67,68]. In addition to decreased HT use, several locations have witnessed a potentially associated decrease in breast cancers.

It is important to recognize that it is difficult for patients to make informed decisions as many people obtain their health information from the media, particularly the internet. The issue is that websites can be of variable quality and may promote anti-evidence-based information [69] or may diminish the risks of HT while highlighting the benefits, or vice versa. As healthcare providers, physicians should either initiate or engage in discussions raised by the patients about HT, and recognize that this is an important opportunity to guide patients to evidence-informed sources of information, such as National women’s health Resource Center, a non-profit resource aimed at providing up-to-date information for

### Table 5. Cont.

| Reference | Media | Work and social contact | Health career |
|-----------|-------|-------------------------|---------------|
| Huang 2010 | | | |
| Lind 2012 | | | |
| Chaopotong 2005 | | | |
| Lam 2003 | | | |
| Jassim 2009 | | | |
| Shiao 2009 | | | |
| Heinemann 2008 | | | |
| Twiss 2007 | | | |
| Deeks 2008 | | | |
women. For women requesting HT, physicians may consider informing women that climacteric symptoms may be short-lasting and benign, and should be aware of the balanced effectiveness and risks of HT based on their individual situations [4].

In conclusion, HT has important adverse events, especially towards breast, many menopausal women are uncertain about the benefits and risks of HT indeed. Sources of reliable information may be an important challenge for patients. As health care providers, it is important to discuss both the benefits and risks with women and make the decision based on their culture, personal experience and readiness, especially in the developing countries.

Providing a standard protocol for administration of HT, routine follow-up health examinations and instituting health teaching prior to prescription may be reasonable steps to assure HT is appropriately used and women remain informed and protected.

Author Contributions
Conceived and designed the experiments: MFT YCT HFS PW EM. Performed the experiments: MFT YCT FHS PW EM. Analyzed the data: MFT YCT HFS PW EM. Contributed reagents/materials/analysis tools: MFT PW EM. Wrote the paper: MFT YCT PW EM.

References
1. Hunt K, Vessey M, McPherson K (1990) Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 97: 1089–1096.
2. Harlap S (1992) The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 166: 1986–1992.
3. Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801–1811.
4. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J (2007) Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 19: 635–641.
5. Huang KE, Xu L, JNN, Jaisamrarn U (2010) The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function. Maturitas 65: 276–283.
6. Olenchak A, Jazwinski IJ, Haspel AA, Everaard WT (1993) Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 168: 772–780.
7. Heinemann K, Kubic A, Strohmann A, Nahum GG, Heinemann LA (2008) Prevalence and opinions of hormone therapy prior to the Women’s Health Initiative: a multinational survey on four continents. J Womens Health (Larchmt) 17: 1151–1166.
8. Hulley S, Grady D, Bush T, Furberg C, Harrington D, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 280: 605–613.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 288: 321–333.
10. International Heart Lung and Blood Institute. Available: http://wwwnhlbi.nih.gov/about/factbook/chapter3.htm.
11. Nelson HD, Humphrey LL, Nguyen P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. Jama 288: 872–881.
12. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, et al. (2010) Estrogen plus progesterin and breast cancer incidence and mortality in postmenopausal women. Jama 304: 1689–1692.
13. Power ML, Anderson BL, Schulkin J (2009) Attitudes of obstetrician-gynecologists toward the evidence from the Women’s Health Initiative hormone therapy trials remain generally skeptical. Menopause 16: 500–508.
14. Fugh-Berman A, McDonald CP, Bell AM, Bemhardt CE, Scialli RA (2011) Promotional Tone in Reviews of Menopausal Hormone Therapy Afer the Women’s Health Initiative: An Analysis of Published Articles. PLoS Med 8: e1004255.
15. Majumdar SR, Alnaim EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. Jama 292: 1983–1988.

Figure 2. Pooled proportions of quantitative studies. doi:10.1371/journal.pone.0024661.g002
Hormone Therapy (HT) in Menopause

16. Hoffmann M, Hammar M, Kjellgren KJ, Lindbl-Andrul L, Bynhldsen J (2005) Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 52: 11–17.

17. Power ML, Einberg S, Schalitin J (2006) A survey of obstetrician-gynaecologists concerning practice patterns and attitudes toward hormone therapy. Menopause 13: 434–441.

18. Rokhlin SJ, Jackson K, Kopher R, Defor TA (2007) Provider management of menopause after the findings of the Women’s Health Initiative. Menopause 14: 411–449.

19. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, et al. (2004) Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 18: 2255–2242.

20. Mills EJ, Montori VM, Ross CP, Shani B, Wilson K, et al. (2005) Systematically reviewing qualitative studies complements survey design: an exploratory study of barriers to paediatric immunisations. J Clin Epidemiol 58: 1101–1108.

21. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, et al. (2006) Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 7: 141–148.

22. Mills E, Jadad AR, Ross C, Wilson K (2005) Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol 58: 1081–1088.

23. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006) Adherence to HAART: a systematic review of developing and developing nation patient-reported barriers and facilitators. PLoS Med 3: e438.

24. Maslow DM, Muyoswalla A, Mills EJ, McGowan J, Attaran A, et al. (2009) Barriers to the effective treatment and prevention of malaria in Africa: A systematic review of qualitative studies. BMC Int Health Hum Rights 9: 26.

25. Boerboom E, Hedges LP, Hupperett J, Rothstein H (2009) Introduction to Meta-analysis. Wiley, Chichester: 312 p.

26. Freeman MF, Turkey JW (1956) Transformations related to the angular and the square root. Ann Math Stat. pp 607–611.

27. Boerboom E, Hedges LP, Hupperett J, Rothstein H Introduction to Meta-analysis.

28. Lam PM, Leung TN, Haines C, Chung TK (2003) Climacteric symptoms and knowledge about hormone replacement therapy among Hong Kong Chinese women aged 40–60 years. Maturitas 45: 99–107.

29. Kaur S, Wala I, Singh A (2004) How menopause affects the lives of women in suburban Chandigarh, India. Climacteric 7: 175–180.

30. Barber CA, Margolis K, Laquevor RP, Arnett DK (2004) The impact of the Women’s Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000–2002). J Womens Health (Larchmtt) 13: 975–985.

31. Obermeyer CM, Reynolds RF, Price K, Abraham A (2004) Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts. Menopause 11: 456–462.

32. Ekstroem HO (2005) Trends in middle-aged women’s reports of symptoms, use of hormone therapy and attitudes towards it. Maturitas 52: 154–164.

33. Filho AS, Soares JMIR, Arkader J, Maciel GA, Baracat EC (2005) Attitudes and knowledge towards daily life and hormone replacement therapy among postmenopausal women. J Pak Med Assoc 58: 164–167.

34. Hovi SL, Hakama M, Veerus P, Rahu M, Hemminki E (2005) Who wants to join preventive trials?–Experience from the Estonian Postmenopausal Hormone Therapy Survey 2005: women’s perceptions on the menopause and hormone therapy. Gynecol Endocrinol 22: 369–375.

35. Hyde A, Nee J, Drennan J, Butler M, Howlett E (2010) Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause 17: 344–350.

36. Lindh-Astrand L, Brynhildsen J, Hoffmann M, Kjellgren KI, Hammar M (2007) Changes in women’s attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 56: 12–20.

37. Lindbl-Andrul L, Bynhldsen J, Hoffmann M, Liffner S, Hammar M (2007) Knowledge of reproductive physiology and hormone therapy in 33- to 43-year-old Swedish women: a population-based study. Menopause 14: 1039–1046.

38. Deeks A, Zoungas S, Teede H (2008) Risk perception in women: a focus on menopause. Menopause 15: 304–309.

39. Malik HS (2008) Knowledge and attitude towards menopause and hormone replacement therapy (HRT) among postmenopausal women. J Pak Med Assoc 58: 164–167.

40. Donati S, Cotichini R, Mosconi P, Satolli R, Colombo C, et al. (2009) Menopause: knowledge, attitude and practice among Italian women. Maturitas 63: 246–252.

41. Hovanan SA, Jarkowska RM, Kirking DM (2009) Women’s trust in and use of information sources in the treatment of menopausal symptoms. Womens Health Issues 19: 144–153.

42. Jassim GA, Al-Shboul QM (2009) Knowledge of Bahraini women about the menopause and hormone therapy: implications for health-care policy. Climacteric 12: 38–48.

43. Simon JA, Reape KZ (2009) Understanding the menopausal experiences of professional women. Menopause 16: 73–76.

44. Ballard K (2002) Understanding risk: women’s perceived risk of menopause-related disease and the value they place on preventive hormone replacement therapy. Fam Pract 19: 591–595.

45. Cúcalí SY, Akmán M, Demirkol A, Unalan PC, Vermeere E (2009) “I should live and finish it”: a qualitative inquiry into Turkish women’s menopause experience. BMC Fam Pract 10: 1–6.

46. French LM, Smith MA, Holtop JS, Holmes-Rovner M (2006) Hormone therapy after the Women’s Health Initiative: a qualitative study. BMC Fam Pract 7: 61.

47. Heyworth J, Paine B, Miles H, Marley J, MacLennan A (2002) The willingness of women to participate in a long-term trial of hormone replacement therapy: A qualitative study using focus groups. Psychology, Health & Medicine 7: 469–476.

48. Hyde A, Nee J, Drennan J, Butler M, Howlett E (2010) Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause 17: 344–350.

49. Kolip P, Hoefling-Engels N, Schmaack N (2009) Attitudes toward postmenopausal long-term hormone therapy. Qual Health Res 19: 207–215.

50. Neldhuyvd L, Bush T, Bononi AE, Ludman EJ, Newton KM (2009) Physicians and women’s views on hormone therapy and breast cancer risk after the WHI: a qualitative study. Women Health 49: 290–293.

51. Shelton AJ, Lees E, Groof JY (2002) Perceptions of hormone replacement therapy among African American women. J Health Care Poor Undersexed 13: 347–559.

52. Welton A, Buntin B, Miles H, Marley J, MacLennan A (2002) The willingness of women to participate in a long-term trial of hormone replacement therapy: A qualitative study using focus groups. Psychology, Health & Medicine 7: 469–476.

53. Hyde A, Nee J, Drennan J, Butler M, Howlett E (2010) Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause 17: 344–350.

54. Kolip P, Hoefling-Engels N, Schmaack N (2009) Attitudes toward postmenopausal long-term hormone therapy. Qual Health Res 19: 207–215.

55. Welton A, Buntin B, Miles H, Marley J, MacLennan A (2002) The willingness of women to participate in a long-term trial of hormone replacement therapy: A qualitative study using focus groups. Psychology, Health & Medicine 7: 469–476.

56. Hyde A, Nee J, Drennan J, Butler M, Howlett E (2010) Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause 17: 344–350.

57. Shelton AJ, Lees E, Groof JY (2002) Perceptions of hormone replacement therapy among African American women. J Health Care Poor Undersexed 13: 347–559.

58. Welton A, Buntin B, Miles H, Marley J, MacLennan A (2002) The willingness of women to participate in a long-term trial of hormone replacement therapy: A qualitative study using focus groups. Psychology, Health & Medicine 7: 469–476.

59. Hyde A, Nee J, Drennan J, Butler M, Howlett E (2010) Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause 17: 344–350.

60. Shelton AJ, Lees E, Groof JY (2002) Perceptions of hormone replacement therapy among African American women. J Health Care Poor Undersexed 13: 347–559.

61. Welton A, Buntin B, Miles H, Marley J, MacLennan A (2002) The willingness of women to participate in a long-term trial of hormone replacement therapy: A qualitative study using focus groups. Psychology, Health & Medicine 7: 469–476.